{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:46:57Z","timestamp":1771937217634,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1136\/ard.2007.072652","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T00:24:34Z","timestamp":1189211074000},"page":"855-859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis"],"prefix":"10.1016","volume":"67","author":[{"given":"V","family":"Ravindran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D L","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E H","family":"Choy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.072652_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"Preliminary definition of improvement in rheumatoid arthritis.","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study.","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomised controlled trials. The CONSORT statement.","volume":"276","author":"Begg","year":"1996","journal-title":"J Am Med Assoc"},{"key":"10.1136\/ard.2007.072652_bib4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/rheumatology\/kei031","article-title":"A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.","volume":"44","author":"Choy E H","year":"2005","journal-title":"Rheumatology"},{"key":"10.1136\/ard.2007.072652_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1136\/ard.2007.072652_bib6","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/archinte.1990.00040031677015","article-title":"Ceftriaxone therapy of chronic inflammatory arthritis: a double-blind placebo controlled trial.","volume":"150","author":"Caperton","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2007.072652_bib7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/1523-1747.ep12875040","article-title":"Treatment of psoriasis and psoriatic arthritis with interferon gamma.","volume":"95","author":"Fierlbeck","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1136\/ard.2007.072652_bib8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/rheumatology\/33.10.954","article-title":"A double-blind placebo controlled trial of efamol marine on skin and joint symptoms of psoriatic arthritis.","volume":"33","author":"Veale","year":"1994","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2003.007104","article-title":"A randomized placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.","volume":"63","author":"Dalbeth","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib10","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard.52.11.826","article-title":"Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis.","volume":"52","author":"McKendry","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib11","first-page":"777","article-title":"Psoriatic arthritis treated with oral colchicine.","volume":"14","author":"Seideman","year":"1987","journal-title":"J Rheumatol"},{"issue":"S22","key":"10.1136\/ard.2007.072652_bib12","first-page":"S17","article-title":"The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide.","volume":"19","author":"Sarzi-Puttini","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":"Methotrexate in patients with psoriatic arthritis: double blind study on 21 patients.","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"key":"10.1136\/ard.2007.072652_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for Psoriatic arthritis. A randomized, double blind, placebo controlled study.","volume":"31","author":"Peeters","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib15","first-page":"2274","article-title":"A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.","volume":"28","author":"Salvarani","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib16","first-page":"589","article-title":"Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.","volume":"13","author":"Spadaro","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02249014","article-title":"Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate.","volume":"13","author":"Bruckle","year":"1994","journal-title":"Clin Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.44.3.189","article-title":"A double blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis.","volume":"44","author":"Hopkins","year":"1985","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double blind, placebo-controlled study.","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","article-title":"A randomized, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis.","volume":"64","author":"Fraser","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib21","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib22","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/rheumatology\/32.10.923","article-title":"Sulfasalazine in the management of psoriatic arthritis.","volume":"32","author":"Fraser","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib23","first-page":"894","article-title":"Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial.","volume":"22","author":"Gupta","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/29.1.46","article-title":"Sulfasalazine in psoriatic arthritis: a double-blind placebo-controlled study.","volume":"29","author":"Farr","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","article-title":"Sulfasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study.","volume":"35","author":"Combe","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/anr.1780320208","article-title":"Evaluation of auranofin in psoriatic arthritis: a double blind placebo controlled trial.","volume":"32","author":"Carrette","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib27","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/rheumatology\/29.4.280","article-title":"A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis.","volume":"29","author":"Palit","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib28","first-page":"116","article-title":"A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis.","volume":"15","author":"Levy","year":"1972","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/rheumatology\/25.2.228","article-title":"d-Penicillamine and psoriatic arthropathy.","volume":"25","author":"Price","year":"1986","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib30","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis.","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1136\/ard.2007.072652_bib32","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib33","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double blind, randomized, placebo-controlled trial.","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib35","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: result of a randomized, double blind, placebo-controlled study.","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib37","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.072652_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis.","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"10.1136\/ard.2007.072652_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials.","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.072652_bib40","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines.","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib41","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review.","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib42","first-page":"1431","article-title":"Therapies for axial disease in psoriatic arthritis. A systematic review.","volume":"33","author":"Nash","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib43","first-page":"1435","article-title":"Therapies for psoriatic enthesopathy. A systematic review.","volume":"33","author":"Ritchlin","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib44","first-page":"1439","article-title":"Therapies for dactylitis in psoriatic arthritis. A systematic review.","volume":"33","author":"Helliwell","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib45","first-page":"1452","article-title":"Therapies for psoriatic nail disease. A systematic review.","volume":"33","author":"Cassell","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib46","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2165\/00003495-200565090-00004","article-title":"Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review.","volume":"65","author":"Gladman","year":"2005","journal-title":"Drugs"},{"key":"10.1136\/ard.2007.072652_bib47","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/36.1.95","article-title":"Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group.","volume":"36","author":"Jones","year":"1997","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib48","series-title":"The Cochrane Library","article-title":"Interventions for treating psoriatic arthritis (Cochrane Review).","author":"Jones","year":"2005"},{"key":"10.1136\/ard.2007.072652_bib49","first-page":"587","article-title":"Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review.","volume":"24","author":"Woolacott","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.072652_bib50","first-page":"1","article-title":"Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.","volume":"10","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724437187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724437187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.072652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:42:30Z","timestamp":1737549750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724437187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0003496724437187"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.072652","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.072652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 2008 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}